Navigation Links
XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512,in Restless Legs Syndrome

SANTA CLARA, Calif.--(BUSINESS WIRE)--Apr 25, 2007 - XenoPort, Inc. (Nasdaq: XNPT) today announced top-line results from a Phase 3 clinical trial of XP13512 for the treatment of symptoms of primary restless legs syndrome (RLS). XP13512 demonstrated statistically significant improvements compared to placebo on both of the co-primary endpoints of the trial and was well tolerated.

"These results are very encouraging and represent a major advance for XenoPort, its partners and, potentially, RLS patients," said Ronald W. Barrett, Ph.D., chief executive officer of XenoPort.

This XenoPort study was a 12-week, double-blind, placebo-controlled Phase 3 clinical trial that enrolled 222 patients who were diagnosed with moderate-to-severe primary RLS. Patients were treated with either 1200 mg of XP13512 or placebo, given once per day. The co-primary endpoints for the clinical trial were the change from baseline for the International RLS (IRLS) rating scale score at end of treatment and the percentage of patients showing significant improvement on the Clinical Global Impression of Improvement (CGI-I) scale at end of treatment.

Treatment with 1200 mg of XP13512 was associated with a statistically significant improvement in the co-primary endpoints compared to placebo. Improvements in the IRLS Scale were significantly greater for XP13512 than for placebo (-13.2 vs. -8.8: p=0.0002). At the end of treatment, significantly more patients treated with XP13512 were reported as "much improved" or "very much improved" on the CGI-I scale compared to those treated with placebo (76% vs. 39%: p less than 0.0001).

During treatment over the 12-week period, the most commonly reported adverse events for XP13512 versus placebo were somnolence (26.5% XP13512; 7.4% placebo) and dizziness (19.5% XP13512; 4.6% placebo). There were no reported serious adverse events in XP13512-treated patients.

Dr. Barrett stated, "XP135
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:9/18/2014)...  KIYATEC announced today that it has been ... (SBIR) Phase II Contract from the National Cancer ... centers that comprise the National Institutes of Health ... award, KIYATEC will expand its 3D breast cancer ... of cancer therapy strategies: 1) cancer,s interaction with ...
(Date:9/18/2014)... Mass. , Sept. 18, 2014  Decision Resources ... anti-vascular endothelial growth factor (VEGF) agent for wet AMD, ... Medicare Advantage plans as Genentech,s Lucentis, which is the ... surveyed managed care organization (MCO) directors do not identify ... is slightly more likely than Lucentis to be listed ...
(Date:9/18/2014)... Sept. 18, 2014  ePharmaSolutions, the leading ... as the Disruptive Innovator of the Year ... eClinical platform. This solution includes an integrated ... file (eTMF), a remote monitoring application, eSource ... patient screening and matching technology. ...
Breaking Medicine Technology:National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 3
... YORK, Dec. 8, 2010 Reportlinker.com announces that ... its catalogue: Asia-Pacific Dental Devices ... http://www.reportlinker.com/p0336613/Asia-Pacific-Dental-Devices-Market-Outlook-to-2016.html Asia-Pacific Dental Devices ... new report, "Asia-Pacific Dental Devices Market Outlook to ...
... 2010 Reportlinker.com announces that a new market research ... China Pharmaceutical Market Overview http://www.reportlinker.com/p0337367/China-Pharmaceutical-Market-Overview.html ... pharma market generated sales of $22.9 billion in 2009, ... and 2009. Key growth drivers include China,s support of ...
Cached Medicine Technology:Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 2Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 3Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 4Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 5Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 6Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 7Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 8Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 9Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 10Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 11Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 12Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 13Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 14Reportlinker Adds Asia-Pacific Dental Devices Market Outlook to 2016 15Reportlinker Adds China Pharmaceutical Market Overview 2Reportlinker Adds China Pharmaceutical Market Overview 3Reportlinker Adds China Pharmaceutical Market Overview 4Reportlinker Adds China Pharmaceutical Market Overview 5Reportlinker Adds China Pharmaceutical Market Overview 6Reportlinker Adds China Pharmaceutical Market Overview 7Reportlinker Adds China Pharmaceutical Market Overview 8Reportlinker Adds China Pharmaceutical Market Overview 9Reportlinker Adds China Pharmaceutical Market Overview 10Reportlinker Adds China Pharmaceutical Market Overview 11Reportlinker Adds China Pharmaceutical Market Overview 12Reportlinker Adds China Pharmaceutical Market Overview 13Reportlinker Adds China Pharmaceutical Market Overview 14Reportlinker Adds China Pharmaceutical Market Overview 15Reportlinker Adds China Pharmaceutical Market Overview 16Reportlinker Adds China Pharmaceutical Market Overview 17
(Date:9/18/2014)... September 19, 2014 A jacket is ... A jacket typically has sleeves, and fastens in the ... generally lighter, tighter-fitting, and less insulating than a coat, ... serve as protective clothing. Today, Fecbek, a well-known clothing ... of trendy men’s jackets; all these items are offered ...
(Date:9/18/2014)... Steven Reinberg HealthDay Reporter , THURSDAY, ... Ebola outbreak in West Africa is starting to spread faster than ... new cases of the deadly viral infection were reported in just ... more than 5,300, with roughly half of those reported in the ... of deaths now tops 2,600. WHO has estimated that as ...
(Date:9/18/2014)... 2014 One of the most capable ... industry, ShandsCair Flight Program’s new EC155 B1, ... (AHI) at the Air Medical Transport Conference (AMTC), Sept. ... placed into service ShandsCair EC155 and the Vanderbilt ... at AMTC highlight Airbus Helicopters broad, industry leading line-up ...
(Date:9/18/2014)... Norton HealthDay Reporter , THURSDAY, ... of a common antidepressant can quickly alter the way brain ... findings, reported online Sept. 18 in Current Biology ... to widely prescribed antidepressants. Experts said the hope is to ... likely to benefit from a drug -- and which people ...
(Date:9/18/2014)... In 2003, the government ... Barrio Adentro), which it hoped would increase ... Section 6.1.3.). In 2009, it invested VEF28 ... of Pharmaceutical Elaborations (Servicio Autónomo de Elaboraciones ... at a cheaper rate than private pharmaceutical ...
Breaking Medicine News(10 mins):Health News:Cool Jackets Are For Sale At Fecbek.com 2Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 2Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 3Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 3Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 4Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 2Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 4
... Calif., May 22 Setaram Inc., a ... analyzers,calorimeters, gas sorption and high pressure mass ... pleased to announce the,appointment of Bruce Jamieson ... the recent acquisition of Hy-Energy LLC (Newark, ...
... Minimally Invasive P3(TM) (Pioneer Peek-on-Peek) ... Technology Motion Preservation Device, DRIEBERGEN, ... announced the BacJac(TM),Interspinous Decompression System (IDS) will be market ... Switzerland., The BacJac system is designed to relieve ...
... May 22 HHS Secretary Mike,Leavitt today announced ... (FDA) and the Centers for Medicare & Medicaid ... patient safety and the quality,of medical care., ... to,monitor the use of medical products on the ...
... PA May 21, 2008 If you were ... works specifically for you" Or a treatment that prevents ... The emerging field of clinical and translational science provides ... patient-specific therapy. Deputy Editor, Scott A. Waldman, MD, PhD, ...
... Accenx Technologies, Inc.,announced today that it ... Program and is now part of Sun,s ... to the healthcare industry. From,this new relationship, ... its already robust client roster, develop a ...
... of today,s,congressional subcommittee hearing on animal-disease research on ... should serve several,purposes:, * Underscore the critical ... real and present threat of diseases that could,harm ... * Demonstrate the urgency of addressing foreign-animal diseases, ...
Cached Medicine News:Health News:Setaram Inc. Appoints New CEO/VP 2Health News:Pioneer(R) Surgical Technology Introduces the BacJac(TM) Interspinous Decompression System to the European Spine Market 2Health News:New Efforts to Help Improve Medical Products for Patient Safety and Quality of Medical Care 2Health News:New Efforts to Help Improve Medical Products for Patient Safety and Quality of Medical Care 3Health News:New Efforts to Help Improve Medical Products for Patient Safety and Quality of Medical Care 4Health News:Unlocking the promise of clinical and translational science 2Health News:Accenx Technologies Joins Sun's Authorized Subcontractor Program 2Health News:Tip Sheet: Kansas Responds to Congressional Hearing on Animal Disease Research 2
Span Diagnostics Limited...
Malaria ( P. Falciparum ) Whole Blood Strip / Cassette...
DiaMed OptiMAL-IT is an immuno-chromatographic test, using monoclonal antibodies against the metabolic enzyme pLDH (parasite lactate dehydrogenase) of Plasmodium spp. These Mabs are classified in t...
Core Malaria Pf is a rapid self performing, qualitative, two site sandwich immunoassay for the determination of P. falciparum specific histidine rich protein 2 (Pf HRP-2) in whole blood samples...
Medicine Products: